Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498551 | 0.88 | NAMPT (0.60) | NAMPTGPR119MAPTSTSPTPN2 | |
| SCHEMBL5440869 | 0.85 | NAMPT (0.57) | NAMPTGPR119STSCDK1CDK2 | |
| SCHEMBL5996576 | 0.85 | TGM2 (0.57) | GPR119MAPTALDH1A1LMNACDK2 | |
| SCHEMBL1871191 | 0.84 | ALDH1A1 (0.61) | NAMPTGPR119MAPTALDH1A1LMNA | |
| SCHEMBL5444087 | 0.82 | NAMPT (0.54) | NAMPTGPR119STSCDK1CDK2 | |
| SCHEMBL5995627 | 0.82 | MAPT (0.51) | MAPTALDH1A1LMNACDK2 | |
| SCHEMBL14490301 | 0.81 | NAMPT (0.51) | NAMPTGPR119CDK1CDK2KDR | |
| SCHEMBL14490275 | 0.81 | NAMPT (0.55) | NAMPTGPR119MAPTCDK1CDK2 | |
| SCHEMBL5423543 | 0.81 | NAMPT (0.48) | NAMPTGPR119MAPTALDH1A1LMNA | |
| SCHEMBL5423545 | 0.81 | NAMPT (0.48) | NAMPTGPR119MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | NAMPT 1021/4885GPR119 1437/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.